Loading...
Presenters at the 2016 San Antonio Breast Cancer Symposium (SABCS; December 6–10, 2016) reported the latest studies in breast cancer. Key findings are summarized below by Dr. William Gradishar, Editor-in-Chief of NEJM Journal Watch Oncology and Hematology. For more information and access to the abstracts, please visit the SABCS website (https://www.sabcs.org).
The optimal duration of adjuvant endocrine therapy was thought to be 5 years, but recent data from the ATLAS trial (NEJM JW Oncol Hematol Jan 2013) and Lancet 2013; 381:805) support durations of tamoxifen as long as 10 years with improvement in clinical endpoints such as disease-free survival (DFS) and overall survival (OS). The optimal du…